IP Library Granted Patent US 7,427,470
Granted Patent B2
US 7,427,470 · App. 10/160,632 · Granted Sep 23, 2008

Antisense modulation of helicase-moi expression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,427,470
App. No.
10/160,632
Granted
Sep 23, 2008
Kind
B2
Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.

Claims (21)

1. A method of decreasing helicase activity in a cell in vitro comprising:

(i) administering to said cell an antisense oligonucleotide 12 to 30 nucleobases in length targeted to nucleotides 4203-4251 of a nucleic acid molecule encoding human helicase-moi (SEQ ID NO: 3); and

(ii) detecting either a decrease in the level of human helicase-moi protein, a decrease in the level of helicase-moi mRNA, or a decrease in helicase-moi activity of said cell.

2. The method of claim 1 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

3. The method of claim 2 wherein the modified internucleoside linkage is a phosphorothioate linkage.

4. The method of claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

5. The method of claim 4 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.

6. The method of claim 1 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

7. The method of claim 6 wherein the modified nucleobase is a 5-methylcytosine.

8. The method of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

9. The method of claim 1 wherein the antisense oligonucleotide is 100% complementary to SEQ ID NO: 3.

10. The method of claim 4 wherein the modified sugar moiety is a bicyclic sugar.

11. The method of claim 1 wherein the antisense oligonucleotide is 20 nucleobases in length.

12. The method of claim 1 wherein the antisense oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5′ wing segment consisting of linked nucleosides; and

a 3′ wing segment consisting of linked nucleosides, wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

13. The method of claim 1 wherein the antisense oligonucleotide comprises:

a gap segment consisting often linked deoxynucleosides;

a 5′ wing segment consisting of five linked nucleosides; and

a 3′ wing segment consisting of five linked nucleosides, wherein the gap segment is positioned between the 5′wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar and wherein each internucleoside linkage is a phosphorothioate linkage.

Assignments (2)
CHANGE OF NAME Recorded Jul 26, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043341/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2004
From: WARD, DONNA T.; WATT, ANDREW T.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 014575/0791 →